The global market for Pharmaceutical Contract Manufacturing is estimated at US$112.4 Billion in 2023 and is projected to reach US$159.8 Billion by 2030, growing at a CAGR of 5.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the pharmaceutical contract manufacturing market is driven by several factors, including the rising demand for generic medicines, the increasing complexity of drug production, and the expansion of the biologics market. As patent cliffs lead to increased generic competition, pharmaceutical companies are turning to CMOs to expedite production and capitalize on market opportunities. The complexity of producing new generations of drugs, especially biologics and personalized medicines, also necessitates specialized capabilities that many pharmaceutical firms find more feasible to outsource.
Additionally, the shift towards personalized medicine is pushing companies to adapt to flexible and scalable production processes, which contract manufacturers are equipped to handle. These trends, combined with the global push for cost efficiency and faster time-to-market, continue to drive significant growth in this sector, highlighting its critical role in the pharmaceutical industry's supply chain.
The growth in the pharmaceutical contract manufacturing market is driven by several factors, including the rising demand for generic medicines, the increasing complexity of drug production, and the expansion of the biologics market. As patent cliffs lead to increased generic competition, pharmaceutical companies are turning to CMOs to expedite production and capitalize on market opportunities. The complexity of producing new generations of drugs, especially biologics and personalized medicines, also necessitates specialized capabilities that many pharmaceutical firms find more feasible to outsource.
Additionally, the shift towards personalized medicine is pushing companies to adapt to flexible and scalable production processes, which contract manufacturers are equipped to handle. These trends, combined with the global push for cost efficiency and faster time-to-market, continue to drive significant growth in this sector, highlighting its critical role in the pharmaceutical industry's supply chain.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the API/Bulk Drugs segment, which is expected to reach US$94.8 Billion by 2030 with a CAGR of a 4.9%. The Advanced Drug Delivery Formulations segment is also set to grow at 4.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $33.9 Billion in 2023, and China, forecasted to grow at an impressive 6.4% CAGR to reach $27.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Pharmaceutical Contract Manufacturing Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pharmaceutical Contract Manufacturing Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Pharmaceutical Contract Manufacturing Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie Inc., Aenova Holding GmbH, Catalent Inc., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 192 Featured):
- AbbVie Inc.
- Aenova Holding GmbH
- Catalent Inc.
- Enteris BioPharma, Inc.
- Jubilant Pharma Ltd.
- Kemwell Biopharma Pvt. Ltd.
- Lifecore Biomedical
- Lonza Group Ltd.
- Thermo Fisher Scientific, Inc.
- WuXi AppTec Co., Ltd.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF ASIA-PACIFICREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
INDIA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Aenova Holding GmbH
- Catalent Inc.
- Enteris BioPharma, Inc.
- Jubilant Pharma Ltd.
- Kemwell Biopharma Pvt. Ltd.
- Lifecore Biomedical
- Lonza Group Ltd.
- Thermo Fisher Scientific, Inc.
- WuXi AppTec Co., Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 528 |
| Published | October 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 112.4 Billion |
| Forecasted Market Value ( USD | $ 159.8 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
